{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T06:54:47Z","timestamp":1793688887639,"version":"4.5.1"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":403,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Bristol Myers Squibb"}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) have high morbidity and mortality; thus, novel treatments are needed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Assess efficacy and safety of admilparant (BMS-986278), an oral lysophosphatidic acid receptor 1 antagonist, in patients with IPF and PPF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This phase 2, randomized, double-blind, placebo-controlled trial included parallel cohorts of patients with IPF (n\u2009=\u2009278 randomized, n\u2009=\u2009276 treated) or PPF (n\u2009=\u2009125 randomized, n\u2009=\u2009123 treated) who received 30 mg of admilparant, 60 mg of admilparant, or placebo (1:1:1) twice daily for 26 weeks. Background antifibrotics (both cohorts) and immunosuppressants (PPF only) were permitted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements and Main Results<\/jats:title>\n                    <jats:p>Rates of change in percentage of predicted FVC over 26 weeks for IPF were \u22122.7% (placebo), \u22122.8% (30 mg), and \u22121.2% (60 mg) and for PPF were \u22124.3% (placebo), \u22122.9% (30 mg), and \u22121.1% (60 mg). Treatment differences between 60-mg admilparant and placebo were 1.4% (95% confidence interval, \u22120.1 to 3.0) for IPF and 3.2% (95% confidence interval, 0.7 to 5.7) for PPF. Treatment effect was observed with or without background antifibrotics in both cohorts. Diarrhea occurred at similar frequencies in admilparant arms versus placebo. Transient Day 1 postdose blood pressure reductions were observed in all arms in both cohorts but were greater with admilparant. Treatment discontinuations because of adverse events were similar across IPF arms and lower with admilparant (2.5% [30 mg]; 0% [60 mg]) versus placebo (17.1%) for PPF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this first phase 2 study to evaluate antifibrotic treatment in parallel IPF and PPF cohorts, 60-mg admilparant slowed lung function decline and was safe and well tolerated, supporting further evaluation in phase 3 trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1164\/rccm.202405-0977oc","type":"journal-article","created":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T17:33:58Z","timestamp":1728668038000},"page":"230-238","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":79,"title":["Efficacy and Safety of Admilparant, an LPA1 Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial"],"prefix":"10.1093","volume":"211","author":[{"given":"Tamera J.","family":"Corte","sequence":"first","affiliation":[{"name":"Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia"},{"name":"University of Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juergen","family":"Behr","sequence":"additional","affiliation":[{"name":"Department of Medicine V, LMU University Hospital, LMU Munich, Member of the German Center for Lung Research, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5591-0955","authenticated-orcid":false,"given":"Vincent","family":"Cottin","sequence":"additional","affiliation":[{"name":"National French Reference Coordinating Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, University Claude Bernard, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilyn K.","family":"Glassberg","sequence":"additional","affiliation":[{"name":"Department of Medicine, Loyola University Chicago Stritch School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kreuter","sequence":"additional","affiliation":[{"name":"Department of Pneumology, Mainz Center for Pulmonary Medicine, Mainz University Medical Center, Mainz, Germany"},{"name":"Department of Pulmonary, Critical Care, and Sleep Medicine, Marienhaus Clinic Mainz, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando J.","family":"Martinez","sequence":"additional","affiliation":[{"name":"Department of Medicine, Weill Cornell Medicine\/New York Presbyterian Hospital, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ogura","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Suda","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlies","family":"Wijsenbeek","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Center for Interstitial Lung Disease and Sarcoidosis, Erasmus University Medical Centre, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elchonon","family":"Berkowitz","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Elpers","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinae","family":"Kim","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aryeh","family":"Fischer","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7192-9149","authenticated-orcid":false,"given":"Toby M.","family":"Maher","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Critical Care, and Sleep Medicine, University of Southern California, Los Angeles, California; and"},{"name":"National Heart and Lung Institute, Imperial College, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,1]]},"reference":[{"key":"2026090309304332100_bib1","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026090309304332100_bib2","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N Engl J Med"},{"key":"2026090309304332100_bib3","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N Engl J Med"},{"key":"2026090309304332100_bib4","doi-asserted-by":"crossref","first-page":"00084-02018","DOI":"10.1183\/23120541.00084-2018","article-title":"Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study","volume":"4","author":"Cottin","year":"2018","journal-title":"ERJ Open Res"},{"key":"2026090309304332100_bib5","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s12931-022-01974-2","article-title":"Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial","volume":"23","author":"Cottin","year":"2022","journal-title":"Respir Res"},{"key":"2026090309304332100_bib6","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S2213-2600(19)30341-8","article-title":"Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"8","author":"Maher","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2026090309304332100_bib7","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S2213-2600(20)30554-3","article-title":"Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial","volume":"9","author":"Behr","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2026090309304332100_bib8","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nm1685","article-title":"The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak","volume":"14","author":"Tager","year":"2008","journal-title":"Nat Med"},{"key":"2026090309304332100_bib9","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1165\/rcmb.2010-0155OC","article-title":"The lysophosphatidic acid receptor LPA1 promotes epithelial cell apoptosis after lung injury","volume":"46","author":"Funke","year":"2012","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2026090309304332100_bib10","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.chest.2018.08.1058","article-title":"Randomized, double-blind, placebo-controlled, phase 2 trial of BMS-986020, a lysophosphatidic acid receptor antagonist for the treatment of idiopathic pulmonary fibrosis","volume":"154","author":"Palmer","year":"2018","journal-title":"Chest"},{"key":"2026090309304332100_bib11","doi-asserted-by":"crossref","first-page":"115885","DOI":"10.1016\/j.taap.2022.115885","article-title":"Mechanism of hepatobiliary toxicity of the LPA1 antagonist BMS-986020 developed to treat idiopathic pulmonary fibrosis: contrasts with BMS-986234 and BMS-986278","volume":"438","author":"Gill","year":"2022","journal-title":"Toxicol Appl Pharmacol"},{"key":"2026090309304332100_bib12","doi-asserted-by":"crossref","first-page":"115846","DOI":"10.1016\/j.taap.2021.115846","article-title":"Structure dependence and species sensitivity of in vivo hepatobiliary toxicity with lysophosphatidic acid receptor 1 (LPA1) antagonists","volume":"438","author":"Sivaraman","year":"2022","journal-title":"Toxicol Appl Pharmacol"},{"key":"2026090309304332100_bib13","first-page":"RCT800","article-title":"BMS-986278 for progressive pulmonary fibrosis (PPF): results from a phase 2 randomized controlled trial [abstract]","volume":"62","author":"Corte","year":"2023","journal-title":"Eur Respir J"},{"key":"2026090309304332100_bib14","first-page":"A2785","article-title":"BMS-986278, an oral lysophosphatidic acid receptor 1 (LPA1) antagonist, for patients with idiopathic pulmonary fibrosis: results from a phase 2 randomized trial [abstract]","volume":"207","author":"Corte","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2026090309304332100_bib15","doi-asserted-by":"crossref","first-page":"e001026","DOI":"10.1136\/bmjresp-2021-001026","article-title":"Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA1) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD)","volume":"8","author":"Corte","year":"2021","journal-title":"BMJ Open Respir Res"},{"key":"2026090309304332100_bib16","first-page":"PA1398","article-title":"BMS-986278, a lysophosphatidic acid 1 (LPA1) receptor antagonist, in healthy participants: a single\/multiple ascending dose (SAD\/MAD) phase 1 study [abstract]","volume":"54","author":"Tirucherai","year":"2019","journal-title":"Eur Respir J"},{"key":"2026090309304332100_bib17","first-page":"e25","article-title":"2017 ACC\/AHA\/HRS guideline for the evaluation and management of patients with syncope: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society","volume":"136","author":"Shen","year":"2017","journal-title":"Circulation"},{"key":"2026090309304332100_bib18","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1164\/rccm.201604-0801CI","article-title":"Acute exacerbation of idiopathic pulmonary fibrosis: an International Working Group report","volume":"194","author":"Collard","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"2026090309304332100_bib19","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1183\/09031936.05.00034805","article-title":"Standardisation of spirometry","volume":"26","author":"Miller","year":"2005","journal-title":"Eur Respir J"},{"key":"2026090309304332100_bib20","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","article-title":"Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials","volume":"377","author":"Noble","year":"2011","journal-title":"Lancet"},{"key":"2026090309304332100_bib21","article-title":"E9(R1) statistical principles for clinical trials: addendum: estimands and sensitivity analysis in clinical trials","author":"US Food and Drug Administration","year":"2021"},{"key":"2026090309304332100_bib22","article-title":"ICH E9 (R1) addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials","author":"European Medicines Agency","year":"2017"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/211\/2\/230\/67293956\/ajrccm_211_2_230.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/211\/2\/230\/67293956\/ajrccm_211_2_230.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T13:30:56Z","timestamp":1788442256000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/211\/2\/230\/8513380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,1]]},"references-count":22,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2,1]]},"published-print":{"date-parts":[[2025,2,1]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.202405-0977oc","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2025,2,1]]},"assertion":[{"value":"2024-05-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}